Infective disorders of the liver

Diseases of the Liver and Biliary System in Children: Third Edition

Volumn , Issue , 2009, Pages 129-168

  Davison, Suzanne ^a   Boxali, Elizabeth H ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889769278     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300536.ch6     Document Type: Chapter

References (214)

1. Kuhns M, Thiers V, Courouce A, Scotto J, Tiollais P. Quantitative detection of HBV DNA in human sera. In: Vyas GN, Dienstag SL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. Orlando, FL: Grune and Stratton, 1984: 665-6.
2. Urdea MS, Horn T, Fultz TJ, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991;24:197-200.
3. Barlet V, Cohard M, Thelu MA, et al. Quantitative detection of hepatitis B DNA in serum using chemiluminescence: comparison with radioactive solution hybridization assay. J Virol Methods 1994;49:141-51.
4. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-68.
5. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 2006;43:S164-72.
6. Bell BP. Hepatitis A vaccine. Pediatr Infect Dis J 2000; 19:1187-8.
7. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979;160: 213-21.
8. Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 1996; 15:4282-96.
9. Lemon SM, Martin A. Structure and molecular virology of hepatitis A. In: Thomas HC, Lemon SM, Zuckerman AJ, eds. Viral Hepatitis. 3rd ed. Oxford: Blackwell, 2005: 79-91.
10. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viraemia in hepatitis A virus infection. J Infect Dis 2000;182:12-7.
11. Maier K, Gabriel P, Koscielniak, et al. Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol 1988;62:3756-63.
12. Gruer LD, McKendrick MW, Beeching NJ, Gedded AM. Relapsing hepatitis associated with hepatitis A. Lancet 1982;2:163.
13. Cobden I, James OFW. A biphasic illness associated with acute hepatitis A virus infection. J Hepatol 1986;2:19-23.
14. Steffen R, Kane MA, Shapiro CN, Billo N, Shoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994;272:885-9.
15. Maguire HC, Handford S, Perry KR, et al. A collaborative case control study of sporadic hepatitis A in England. Commun Dis Rep CDR Rev 1995;5:R33-40.
16. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to activate viruses. Ann Intern Med 1993;120:1-7.
17. Noble RC, Kane MA. Posttransfusion hepatitis A in neonatal intensive care unit. JAMA 1984;252:2711-5.
18. Lee KK, Vargo LR, Lê CT, Fernando L. Transfusion-acquired hepatitis A outbreak from fresh plasma in a neonatal intensive care unit. Pediatr Infect Dis J 1992;11:122-3.
19. Urganci N, Arapoglu M, Akyildiz B, Nuhoglu A. Neonatal cholestasis resulting from vertical transmission of hepatitis A infection. Pediatr Infect Dis J 2003;22:381-2.
20. Yotsuyanagi H, Koike K, Yasuda K, et al. Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology 1996; 24:10-3.
21. Fujiwara K, Yokosuka O, Ehata T, et al. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology 1997;26:1634-9.
22. Debray D, Cullufi P, Devictor D, Fabre M, Bernard O. Liver failure in children with hepatitis A. Hepatology 1997;26:1018-22.
23. Corpechot C, Cadranel JF, Hoang C, et al. [Cholestatic viral hepatitis A in adults. Clinical, biological and histopathological study of 9 cases; in French.] Gastroenterol Clin Biol 1994;18:743-50.
24. Keeffe E. Hepatitis A in patients with chronic liver disease-severity of illness and prevention with vaccination. J Viral Hepat 2000;7(Suppl 1):15-7.
25. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
26. Salisbury D, Ramsay M, Noakes K, eds. Immunisation against Infectious Disease. 3rd ed. London: TSO, 2006.
27. Kane MA, Clements J, Hu D. Hepatitis B. In: Jamison DT, Mosley WH, Measham AR, Bobadilla J. Disease Control Priorities in Developing Countries. New York: Oxford University Press, 1993: 321-30.
28. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
29. Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol 2006;78:S36-S42.
30. Thursz MR, Howard HC. Pathogenesis of chronic hepatitis B virus infection. In: Thomas HC, Lemon SM, Zuckerman AJ, eds. Viral Hepatitis. 3rd ed. Oxford: Blackwell, 2005: 308-22.
31. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly DA. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ 1992;304:1169-70.
32. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1987;147:185-90.
33. Balkaran BN, Teelucksingh S, Singh VR. Hepatitis B-associated polyarteritis nodosa and hypertensive encephalopathy. West Indian Med J 2000;49:170-1.
34. Wilson's RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997;92:3-17.
35. Liu CJ, Lo SC, Kao JH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006;44:39-46.
36. Chu CM, Karayiannis P, Fowler MJ, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-4.
37. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997;12: S218-222.
38. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
39. Lau DTY, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
40. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
41. Merican I. Management of chronic hepatitis B. Treatment of chronic hepatitis B virus infection in special groups of patients: decompensated cirrhosis, immunosuppressed and paediatric patients. J Gastroenterol Hepatol 2000;15(Suppl):E71-8.
42. Sira JK, Boxall E, Sleight E, Ballard A, Yoong AK, Kelly DA. Long-term treatment of chronic hepatitis B carrier children in the UK [abstract]. Hepatology 1997;26:427A.
43. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or without steroid pre-treatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996;23:700-7.
44. Yokosuka O. Role of steroid priming in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2000; 15 (Suppl):E41-5.
45. Lok A. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;132:1586-94.
46. Leung, N. Liver disease-significant improvement with lamivu-dine. J Med Virol 2000;61:380-5.
47. Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivu-dine for chronic hepatitis B. N Engl JMed 1998;339:61-8.
48. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28:388A.
49. Deinstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
50. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-4.
51. Moraleda G, Saputelli J, Aldrich CE, Averett, D, Condreay L, Mason WS. Lack of effect of antiviral therapy in non-dividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.
52. Kock J, Schlicht HJ. Analysis of the earliest steps of hepad-navirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993;67:4867-74.
53. De Jong MD, Boucher CAB, Danner SA, et al. Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Res 1998;37: 1-16.
54. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
55. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adults with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-7.
56. Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lam-ivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
57. Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32.
58. Calio R, Villani E, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23:77-89.
59. Perillo R, Schiff E, Magill A, Murray A. In vivo demonstration of sensitivity of YMDD variants to adefovir. Gastroenterology 1999;116:A1261.
60. Sokal E, Jonas M, Kelly D, et al. Safety, efficacy and pharma-cokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18) with chronic hepatitis B [abstract]. J Pediatr Gastroenterol Nutr 2007;44:e28.
61. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 2006;66:1605-22.
62. Colonno R, Rose R, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients [abstract]. Hepatology 2006;44:229A-230A.
63. Mutimer D, Dowling D, Cane O, et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antiviral Ther 2000;5:273-7.
64. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46: 562-8.
65. D'Antiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G. Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228-33.
66. Jara P, Bortolotti F. Interferon-(alpha) treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29: 163-70.
67. Al-Taie OH, Mörk H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 1999;78:247-9.
68. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy- pathogenesis and management. Rev Med Virol 2001;11:287-99.
69. Kawai Y, Ikegaya S, Hata M, et al. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann Hematol 2001;80:482-4.
70. Saif MW, Little RF, Hamilton JM, Allegra CJ, Wilson's WH. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann Oncol 2001;12: 123-9.
71. Demetris AJ, Jaffe R, Sheahan DG, et al. Recurrent hepatitis B in liver allograft recipients: differentiation between viral hepatitis B and rejection. Am J Pathol 1986;125:161-72.
72. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23:1031-41.
73. Brechot C, Bernuau J, Thiers V, et al. Multiplication of hepatitis B virus in fulminant hepatitis B. BMJ 1984;288:270-1.
74. Schmitz V, Qian C, Ruiz J, et al. Gene therapy for liver disease: recent strategies for treatment of viral hepatitis and liver malignancies. Gut 2002;50:130-5.
75. Lin YC, Chang MW, Ni YH, Hsu HY, Cheng DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187:134-8.
76. Boxall EH, Sira J, El-Shukri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004;190:1264-9.
77. Banatvala JE, Chrystie IL, Palmer SJ, Kenney A. Retrospective study of HIV, hepatitis B and HTLV-1 at a London antenatal clinic. Lancet 1990;335:859-60.
78. Boxall EH. Antenatal screening for carriers of hepatitis B virus. BMJ 1995;311:1178-9.
79. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.
80. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
81. Great Britain. Expert Advisory Group on AIDS. Guidance for Clinical Health Care Workers: Protection against Infection with Blood-Borne Viruses: Recommendations of the Expert Advisory Group on AIDS and the Advisory Group on Hepatitis. London: Department of Health, 1998.
82. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002;67:433-9.
83. Zanetti AR, Mariano A, Romano L, et al. Long-term immuno-genicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-84.
84. Wallace LA, Young D, Brown A, et al. Costs of running a universal adolescent hepatitis B vaccination programme. Vaccine 2005;23: 5624-31.
85. Zuckerman J, van Hattum J, Cafferkey M, et al. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infect Dis 2007;7:410-9.
86. Rubin L, Hefer E, Dubnov Y, Warman S, Rishpon S. An evaluation of the efficacy of the national immunization programme for hepatitis B. Public Health 2007;121:529-33.
87. Bortolotti F, Iorio R, Resti M, et al. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Pediatr Gastroenterol Nutr 2001;32:562-6.
88. Bunn SK, Sira J, Kelly DA. Paediatric hepatitis C-a single centre experience. J Pediatr Gastroenterol Nutr 2002;32:432.
89. National Institute for Clinical Excellence. Guidance on the Use of Ribavirin and Interferon Alpha for Hepatitis C. London: National Institute for Clinical Excellence, 2000. (Technology appraisal guidance, no. 14.)
90. Wreghitt TG, Gray JJ, Allain JP, et al. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994;20:768-72.
91. Tillmann HL, Manns MP. Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci 1996;41:27S-40S.
92. Tedder RS, Briggs M, Ring C, et al. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 1991;79:512-5.
93. Ades AE, Parker S, Walker J, Cubitt WD, Jones R. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000; 125:399-405.
94. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-9.
95. European Paediatric Hepatitis C Virus Network. Effects of mode and delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG 2001;108:371-7.
96. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to- child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-7.
97. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ 1998;317:437-41.
98. Boxall EH, Baumann K, Price N Sira J, Brown M, Kelly D. Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies. J Clin Virol 2007;38:91-5.
99. Maccabruni A, Bossi G, Caselli D, et al. High efficiency of vertical transmission of hepatitis C virus among babies born to human immunodeficiency virus-negative women. Pediatr Infect Dis J 1995;14:921-2.
100. Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995;14:195-9.
101. Tovo PA, Palombo E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women co-infected with human immunodeficiency virus type 1. Clin Infect Dis1997; 25:1121-4.
102. Ruiz-Extremera A, Salmeron J, Torres C, et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000;19:511-6.
103. Macias J, Mira JA, López-Cortés LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis. Antivir Ther 2006;11:839-46.
104. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child 2006;91:781-5.
105. Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl J Med 2000;342:290-1.
106. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. Histopathologic findings in chronic hepatitis C. J Hepatol 1996;24(2 Suppl):35-42.
107. Thaler MM, Hu F, Heyman, M.B. Giant cell hepatitis due to hepatitis C infection. Hepatology 1992;16:74A.
108. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
109. Harris HE, Ramsay ME, Heptonstall J, Soldan K, Eldridge KP. The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. J Viral Hepat 2000;7: 420-7.
110. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-3.
111. Wiese M, Grungieff K, Guthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicentre study. J Hepatol 2005;43:590-6.
112. Tovo PA, Pembrey LJ, Mewell ML. Persistence rate and progression of vertically acquired hepatitis C infection. J Infect Dis 2000;181:419-24.
113. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80.
114. Bortolotti F, Resti M, Marcellini M, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection; changing distribution and correlation with clinical features and outcome. Gut 2005;54:825-7.
115. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005;41:45-51.
116. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl JMed 1999;341:866-70.
117. Casiraghi MA, De Paschale M, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004;39:90-6.
118. Bunn S, Hubscher S, Kelly, D. The progression of hepatic inflammation and fibrosis in children with hepatitis C. J Pediatr Gastroenterol Nutr 2000;31:203.
119. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003;98:660-3.
120. Badizadegan K, Jonas MM, Ott JJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416-23.
121. Harris HE, Mieli-Vergani G, Kelly D, Davison S, Gibb DM, Ramsay ME. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45:335-41.
122. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615-20.
123. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34:52-8.
124. Nieforth KA, Nadeau R, Patal IH, Mould D. Use of an indirect pharmacodynamic simulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636-46.
125. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006;43: 499-505.
126. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database Syst Rev 2002;(2):CD002234.
127. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53.
128. Christensson B, Wiebe T, Akesson A, Widell A. Interferonalpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000;30:585-6.
129. Woynarowski M, Socha J, Kuydowicz J, et al. Interferon and ribavirin versus interferon alone in treatment of chronic HCV infection in children. J Pediatr Gastroenterol Nutr 2001;32:48.
130. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for children with chronic hepatitis C in children: efficacy, safety and pharmacokinetics. Hepatology 2005;42:1010-8.
131. Suoglu D, Elkabes B, Sokucu S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002;34:199-206.
132. Wirth S, Gehring S, Lang T, Gerner P. Treatment with alfainterferon and ribavirin improves the response rate in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34: 439.
133. National Institute for Health and Clinical Excellence (Great Britain). Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. London: National Institute for Health and Clinical Excellence, 2006. (NICE Technology Appraisal Guidance, Quick Reference Guide 106.)
134. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002;347:975-83.
135. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8.
136. McHutchison JG, Manns MP, Brown RS, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007;102:880-9.
137. Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000;19:22-30.
138. Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalas-saemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005;130:644-6.
139. Butensky E, Pakbaz Z, Foote D, Walters MC, Vichinsky EP, Harmatz P. Treatment of hepatitis C virus infection in tha-lassemia. Ann N Y Acad Sci 2005;1054:290-9.
140. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006;57:8-13. Erratum in J Antimicrob Chemother 2006;58:488.
141. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-8.
142. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436: 953-60.
143. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6.
144. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294-9.
145. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
146. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-6.
147. Chang MH, Hadzic D, Rouassant SH, et al. Acute and chronic hepatitis: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004;39(Suppl 2):S584-8.
148. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral hepatitis (Eurohep) Gut 2000;46:420-6.
149. Farci P, Barbera C, Navone C, et al. Infection with delta agent in children. Gut 1985;26:4-7.
150. Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101:1649-55.
151. Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007;44:e17-24.
152. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl JMed 1997;336:347-56.
153. Arora NK, Panda SK, Nanda SK, et al. Hepatitis E infection in children: study of an outbreak. J Gastroenterol Hepatol 1999; 14: 572-7.
154. Dalton HR, Thurairajah PH, Fellows HJ, et al. Autochthonous hepatitis E in southwest England. J Viral Hepat 2007;14:304-9.
155. Khuroo MS, Kamili S, Jameel S. Vertical transmission of hepatitis E virus. Lancet 1995;345:1025-6.
156. Ijaz S, Arnold E, Banks M, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical and molecular epidemiological characteristics. J Infect Dis 2005;192:1166-72.
157. Banks M, Heath GS, Grierson SS, et al. Evidence for the presence of hepatitis E virus in pigs in the United Kingdom. Vet Rec 2004;154:223-7.
158. Jaroszewicz J, Flisiak R, Kalinowska A, Wierzbicka I, Prokopowicz D. Acute hepatitis E complicated by pancreatitis: a case report and literature review. Pancreas 2005;30:382-4.
159. Zamvar V, McClean P, Odeka E, Richards M, Davison S. Hepatitis E virus infection with non-immune haemolytic anemia. J Pediatr Gastroenterol Nutr 2005;40:1-3.
160. Hamid SS, Atiq M, Shehzad F, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002;36:474-8.
161. Peron JM, Danjoux M, Kamar N, et al. Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Archiv 2007;450:405-10.
162. Favorov MO, Fields HA, Purdy MA, et al. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol 1992;36:246-50.
163. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356;895-903.
164. Fagan EA, Ellis DS, Tovey GM, et al. Toga-like virus as a cause of fulminant hepatitis attributed to sporadic non-A, non-B. J Med Virol 1989;28:150-5.
165. Fagan EA, Ellis DS, Tovey GM, et al. Toga virus-like particles in acute liver failure attributed to sporadic non-A, non-B hepatitis and recurrence after liver transplantation. J Med Virol 1992;38: 71-7.
166. Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
167. Lin HH, Kao JH, Chen PJ, Chen DS. Mechanism of vertical transmission of hepatitis G [letter]. Lancet 1996;347:1116.
168. Davison SM, Skidmore SJ, Collingham KE, Irving WL, Hubscher SG, Kelly DA. Chronic hepatitis in children after liver transplantation: role of hepatitis C virus and hepatitis G virus infections. J Hepatol 1998;28:764-70.
169. Sottini A, Mattioli S, Fiordalisis G, Imberti L, Moratto D, Primi D. Molecular and biological characterisation of SEN viruses: a family of viruses remotely related to the original TTV isolates. In: Margolis HS, Alter MJ, Liang TJ, Deinstag JL, eds. Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. Atlanta: International Medical Press, 2002:449-452.
170. Nishizawa T, Okamoto M, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown origin. Biochem Biophys Res Commun 1997:241:92-7.
171. Moriondo M, Resti M, Betti L, et al. SEN virus co-infection among HCV-RNA-positive mothers, risk of transmission to the offspring and outcome of child infection during a 1-year follow-up. J Viral Hepat 2007;14:355-9.
172. Hino S, Miyata H. Torque teno virus (TTV): current status. Rev Med Virol 2007;17:45-57.
173. Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr 2005;40:575-81.
174. Squires RH, Shneider B, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-8.
175. Iterbeek P, Vandenberghe P, Nevens F, et al. Aplastic anaemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. Transpl Int 2002;15:117-23.
176. Khatib R, Siddique M, Abbass M. Measles-associated hepatobiliary disease: an overview. Infection 1993;21:112-4.
177. Makhene MK, Diaz PS. Clinical presentation and complications of suspected measles in hospitalized children. Pediatr Infect Dis J 1993;12:836-40.
178. Papadopoulou AL, Theodoridou M, Syriopoulou V, Mostron G, Kattamis CH. Hepatitis in children hospitalized with measles: the experience acquired after a Greek epidemic. J Paediatr Child Health 2001;37:55-7.
179. Vento S, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. Am J Gastroenterol 1996;91:2618-20.
180. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S. Human parvovirus B 19 infection associated with acute hepatitis. Lancet 1996;347:868-9.
181. Naides SJ, Karetnyi YV, Cooling LL, Mark RS, Langnas AN. Human parvovirus B19 infection and hepatitis. Lancet 1996; 347:1563-4.
182. Markin RS. Manifestations of Epstein-Barr virus-associated disorders in liver. Liver 1994;14:1-13.
183. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187:527-33.
184. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006;16:251-61.
185. Kimberlin DW. Human herpesviruses 6 and 7: identification of newly recognized viral pathogens and their association with human disease. Pediatr Infect Dis J 1998;17:59-68.
186. Eksborg S, Pal N, Kalin M, Palm C, Söderhäll S. Pharmaco-kinetics of acyclovir in immunocompromised children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002;38:240-6.
187. Frenkel LM, Capparelli EV, Dankner WM, et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis 2000;182:1616-24.
188. Castagnola E, Cristina E, Dufour C. High-dose oral ganciclovir for management of CMV-symptomatic infection in a child with acute lymphoblastic leukemia. Med Pediatr Oncol 2002;38:295-6.
189. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388-92.
190. Brundler MA, Rodriguez BN, Jaffe R, Weinberg AG, Rogers BB. Adenovirus ascending cholangiohepatitis. Pediatr Dev Pathol 2003;6:156-9.
191. Seidemann K, Heim A, Pfister ED, et al. Monitoring of adeno-virus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant 2004;4:2102-8.
192. Chou LL, Chang CP, Wu LC. Neonatal coxsackievirus B1 infection associated with severe hepatitis: report of three cases. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1995;36:296-9.
193. Haddad J, Gut JP, Wendling MJ, et al. Enterovirus infection in neonates. A retrospective study of 21 cases. Eur J Med 1993; 2:209-14.
194. Kadrofske M, Parimi P, Myers M, Kumar ML, Abughali N. Nonimmune hydrops fetalis and hepatitis in a neonate with congenital human immunodeficiency virus infection. Pediatr Infect Dis J 2006;25:952-4.
195. Persaud D, Bangaru B, Greco MA, et al. Cholestatic hepatitis in children infected with the human immunodeficiency virus. Pediatr Infect Dis J 1993;12:492-8.
196. Nigro G, Taliani G, Krzysztofiak A, et al. Multiple viral infections in HIV infected children with chronically evolving hepatitis. Arch Virol 1993;8:237-48.
197. Haydon GH, Mutimer DJ. Hepatitis B and C virus infections in the immune compromised. Curr Opin Infect Dis 2003;16:473-9.
198. Mauss S. Treatment of viral hepatitis in HIV-coinfected patients -adverse events and their management. J Hepatol 2006;44(1 Suppl):S114-8.
199. Poovorawan Y, Hutagalung Y, Chongsrisawat V, Boudville I, Bock HL. Dengue virus infection: a major cause of acute hepatic failure in Thai children. Ann Trop Paediatr 2006;26:17-23.
200. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
201. Ismail TF, Wasfy MO, Abdul RB, et al. Retrospective serosurvey of leptospirosis among patients with acute febrile illness and hepatitis in Egypt. Am J Trop Med Hyg 2006;75:1085-9.
202. Covic A, Maftei ID, Gusbeth TP. Acute liver failure due to leptospirosis successfully treated with MARS dialysis. Int Urol Nephrol 2007;39:313-6.
203. Murano I, Yoshii H, Kurashige K, Sugio Y, Tsukahara M. Giant hepatic granuloma caused by Bartonella henselae. Pediatr Infect Dis J 2001;20:319-20.
204. Craft JC, Ruff AJ. Protozoan infections. In: Nelson BC, ed. Current Therapy in Paediatric Infectious Disease, vol. 2. Toronto: Decker, 1988:??-??.
205. Sailer M, Soelder B, Allerberger F, Zaknun D, Feichtinger H, Gottstein B. Alveolar echinococcosis of the liver in a six-year-old girl with acquired immunodeficiency syndrome. J Pediatr 1997;130:320-3.
206. Bari S, Sheikh KA, Ashraf M, Hussain Z, Hamid A, Mufti GN. Ascarisliver abscess in children. J Gastroenterol 2007;42:236-40.
207. Pawlowski ZS. Roundworm infections. In: Nelson BC, ed. Current Therapy in Paediatric Infectious Disease, vol. 2. Toronto: Decker, 1988:??-??.
208. Markell EK. Trematode infections. In: Nelson BC, ed. Current Therapy in Paediatric Infectious Disease, vol. 2. Toronto: Decker, 1988:??-??.
209. Barnes PF, De Cock KM, Reynolds TN, Ralls PW. A comparison of amebic and pyogenic abscess of the liver. Medicine 1987;66: 472-83.
210. Wolfsen HC, Bolen JW, Bowen JL, Fenster LF. Fulminant herpes hepatitis mimicking hepatic abscesses. J Clin Gastroenterology 1993; 16:61-4.
211. Garcia-Eulate R, Hussain N, Heller T, et al. CT and MRI of hepatic abscess in patients with chronic granulomatous disease. AJR Am J Roentgenol 2006;187:482-90.
212. Doerr CA, Demmler GJ, Garcia-Prats JA, Brandt ML. Solitary pyogenic liver abscess in neonates: report of three cases and review of the literature. Pediatr Infect Dis J 1994;13:64-9.
213. Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 2002;235:383-91.
214. Erdman SH, Barber BJ, Barton LL. Aspergillus cholangitis: a late complication after Kasai portoenterostomy. J Pediatr Surg 2002; 37:923-5.